Anesthesiology Doctors in Jackson, WY Accepting Medicare

4 Anesthesiology doctors found. Showing 1 - 4

Charles Lee Payne, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 970 W Broadway # 378, Jackson, WY 83001 Phone: 307-734-6956

Philip C Blum, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 150 Buffalo Way, Jackson, WY 83002 Phone: 307-733-8677

Marc F Domsky, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 625 E Broadway, Jackson, WY 83001 Phone: 307-739-7218

Dr. David J Tomlinson, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 625 E Broadway, Jackson, WY 83002 Phone: 307-739-7218    Fax: 307-739-7446

News Archive

How cancer impacts patients and their partners

Katarina Sjövall has studied partners of individuals with colorectal cancer, lung cancer, breast cancer or prostate cancer. The study shows that the number of diagnosed diseases among partners increased by 25 per cent after the cancer diagnosis.

Biotage launches ISOLUTE SLE+ sample preparation columns

Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announced the introduction of ISOLUTE SLE+ High-Performance Supported Liquid Extraction sample preparation columns. The announcement occurred during the 58th ASMS Conference on Mass Spectrometry and Allied Topics in Salt Lake City, Utah USA.

Higher sugar-sweetened beverage intake, not diet soda linked to risk of developing prediabetes

Adult Americans who regularly consumed sugar-sweetened beverages (roughly one can of soda per day) had a 46 percent higher risk of developing prediabetes compared to low- or non-consumers over a 14-year period, according to a new epidemiological analysis led by scientists at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University.

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

New research shows that spontaneous mutations contribute to congenital heart disease

Every year, thousands of babies are born with severely malformed hearts, disorders known collectively as congenital heart disease. Many of these defects can be repaired though surgery, but researchers don't understand what causes them or how to prevent them. New research shows that about 10 percent of these defects are caused by genetic mutations that are absent in the parents of affected children.

Read more Medical News

› Verified 3 days ago